Schuyler van den Broek

Research Analyst at Piper Sandler & Co.

Schuyler van den Broek was an Analyst-Equity at Piper Sandler & Co. from 2022 to 2024, specializing in coverage within the firm’s focus sectors, including agriculture, renewables, business services, chemicals, consumer, diversified industrials, energy, financial services, healthcare, and technology. She contributed to research on select companies across these sectors, supporting investment recommendations and sector analysis, though individual company names and performance rankings have not been publicly disclosed. Van den Broek began her career after earning an undergraduate degree from the University of Michigan in 2020, joining Piper Sandler in 2022 and departing in 2024. She holds an undergraduate degree but no public record of FINRA registration or securities licenses is available.

Schuyler van den Broek's questions to OPTN leadership

Question · Q1 2024

May 14, 2024

Asked about the payer landscape post-label expansion, the long-term evolution of net revenue per prescription, and the factors that would drive a sales force expansion.

Answer

Executives stated it's too early for broad payer feedback but anecdotes are positive, with the new indication being added to prior authorization forms. Net revenue per prescription is driven by business actions like co-pay programs, not the label itself. A potential sales force expansion will be based on data and ROI from the current launch efforts.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies

Access millions of SEC filings & transcripts

Get answers cited to the source

Try Fintool for Free

Trusted by leading investment firms and analysts